Phase I study of AG-120, an IDH1 mutant enzyme inhibitor: Results from the cholangiocarcinoma dose escalation and expansion cohorts.

被引：0
|
作者：
Lowery, Maeve Aine
Abou-Alfa, Ghassan K.
Burris, Howard A.
Janku, Filip
Shroff, Rachna T.
Cleary, James M.
Azad, Nilofer Saba
Goyal, Lipika
Maher, Elizabeth A.
Gore, Lia
Hollebecque, Antoine
Beeram, Muralidhar
Trent, Jonathan C.
Jiang, Liewen
Ishii, Yuko
Auer, Julia
Gliser, Camelia
Agresta, Samuel V.
Pandya, Shuchi Sumant
Zhu, Andrew X.
机构：
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2017年 / 35卷
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
4013
引用
收藏
页数：6
相关论文
共 50 条
  • [41] Phase I Study of the Mutant IDH1 Inhibitor Ivosidenib: Safety and Clinical Activity in Patients With Advanced Chondrosarcoma
    Tap, William D.
    Villalobos, Victor M.
    Cote, Gregory M.
    Burris, Howard
    Janku, Filip
    Mir, Olivier
    Beeram, Murali
    Wagner, Andrew J.
    Jiang, Liewen
    Wu, Bin
    Choe, Sung
    Yen, Katharine
    Gliser, Camelia
    Fan, Bin
    Agresta, Sam
    Pandya, Shuchi S.
    Trent, Jonathan C.
    JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (15) : 1693 - +
  • [42] A first-in-human phase 1 study of LY3410738, a covalent inhibitor of mutant IDH1 and IDH2, as monotherapy and in combination with cisplatin and gemcitabine in advanced IDH-mutant cholangiocarcinoma
    Harding, J.
    Ikeda, M.
    Goyal, L.
    Rodon, J.
    Bai, L.
    Oh, D.
    Park, J.
    Chen, L.
    Ueno, M.
    Liao, C.
    Kondo, S.
    Cosman, R.
    Yokota, T.
    Shroff, R.
    Satoh, T.
    Palmieri, L.
    Hollebecque, A.
    Adeva, J.
    Bender, M.
    Liu, H.
    Macarulla, T.
    ANNALS OF ONCOLOGY, 2023, 34 : S161 - S161
  • [43] A phase I study of LY3410738, a first-in-class covalent inhibitor of mutant IDH1 in cholangiocarcinoma and other advanced solid tumors.
    Pauff, James Michael
    Papadopoulos, Kyriakos P.
    Janku, Filip
    Turk, Anita Ahmed
    Goyal, Lipika
    Shroff, Rachna T.
    Shimizu, Toshio
    Ikeda, Masafumi
    Azad, Nilofer Saba
    Cleary, James M.
    Peters, Mary Linton Bounetheau
    Borad, Mitesh J.
    Jaeckle, Kurt A.
    Kizilbash, Sani Haider
    Tupper, Rebecca
    Furin, Carrie E.
    Hanley, Matthew P.
    Hill, Elizabeth Goodwin
    Xu Xiaojian
    Harding, James J.
    JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (03)
  • [44] Dose escalation and expansion cohorts in patients with advanced breast cancer in a Phase I study of the CDK7-inhibitor samuraciclib
    Coombes, R. Charles
    Howell, Sacha
    Lord, Simon R.
    Kenny, Laura
    Mansi, Janine
    Mitri, Zahi
    Palmieri, Carlo
    Chap, Linnea I.
    Richards, Paul
    Gradishar, William
    Sardesai, Sagar
    Melear, Jason
    O'Shaughnessy, Joyce
    Ward, Patrick
    Chalasani, Pavani
    Arkenau, Tobias
    Baird, Richard D.
    Jeselsohn, Rinath
    Ali, Simak
    Clack, Glen
    Bahl, Ashwani
    McIntosh, Stuart
    Krebs, Matthew G.
    NATURE COMMUNICATIONS, 2023, 14 (01)
  • [45] ENASIDENIB (AG-221) IN MUTANT-IDH2 RELAPSED OR REFRACTORY ACUTE MYELOID LEUKEMIA (R/R AML): RESULTS OF A PHASE 1 DOSE-ESCALATION AND EXPANSION STUDY
    Stein, E. M.
    DiNardo, C. D.
    Pollyea, D. A.
    Fathi, A. T.
    Roboz, G. J.
    Altman, J. K.
    Stone, R. M.
    Flinn, I. W.
    Kantarjian, H. M.
    Collins, R.
    Patel, M. R.
    Stein, A.
    Sekeres, M. A.
    Swords, R. T.
    Medeiros, B. C.
    Knight, R. D.
    Agresta, S.
    de Botton, S.
    Tallman, M. S.
    HAEMATOLOGICA, 2017, 102 : 175 - 175
  • [46] Pharmacokinetics/pharmacodynamics (PK/PD) of ivosidenib in patients with mutant IDH1 advanced cholangiocarcinoma from the phase III ClarIDHy study
    Fan, Bin
    Abou-Alfa, Ghassan K.
    Zhu, Andrew X.
    Pandya, Shuchi Sumant
    Jia, Hongxia
    Yin, Feng
    Jiang, Liewen
    Gliser, Camelia
    Yang, Hua
    JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (04)
  • [47] Vorasidenib, a Dual Inhibitor of Mutant IDH1/2, in Recurrent or Progressive Glioma; Results of a First-in-Human Phase I Trial
    Mellinghoff, Ingo K.
    Penas-Prado, Marta
    Peters, Katherine B.
    Burris, Howard A.
    Maher, Elizabeth A.
    Janku, Filip
    Cote, Gregory M.
    de la Fuente, Macarena, I
    Clarke, Jennifer L.
    Ellingson, Benjamin M.
    Chun, Saewon
    Young, Robert J.
    Liu, Hua
    Choe, Sung
    Lu, Min
    Le, Kha
    Hassan, Islam
    Steelman, Lori
    Pandya, Shuchi S.
    Cloughesy, Timothy F.
    Wen, Patrick Y.
    CLINICAL CANCER RESEARCH, 2021, 27 (16) : 4491 - 4499
  • [48] AG-120, an Oral, Selective, First-in-Class, Potent Inhibitor of Mutant IDH1, Reduces Intracellular 2HG and Induces Cellular Differentiation in TF-1 R132H Cells and Primary Human IDH1 Mutant AML Patient Samples Treated Ex Vivo
    Hansen, Erica
    Quivoron, Cyril
    Straley, Kim
    Lemieux, Rene M.
    Popovici-Muller, Janeta
    Sadrzadeh, Hossein
    Fathi, Amir T.
    Gliser, Camelia
    David, Muriel
    Saada, Veronique
    Micol, Jean-Baptiste
    Bernard, Olivier
    Dorsch, Marion
    Yang, Hua
    Su, Michael
    Agresta, Sam
    de Botton, Stephane
    Penard-Lacronique, Virginie
    Yen, Katharine
    BLOOD, 2014, 124 (21)
  • [49] Enasidenib in mutant-IDH2 relapsed or refractory acute myeloid leukemia (R/R AML): Results of a phase I dose-escalation and expansion study.
    Stein, Eytan M.
    Dinardo, Courtney Denton
    Pollyea, Daniel Aaron
    Fathi, Amir Tahmasb
    Roboz, Gail J.
    Altman, Jessica K.
    Stone, Richard M.
    Flinn, Ian
    Kantarjian, Hagop M.
    Collins, Robert
    Patel, Manish R.
    Stein, Anthony Selwyn
    Sekeres, Mikkael A.
    Swords, Ronan T.
    Medeiros, Bruno C.
    Knight, Robert D.
    Agresta, Samuel V.
    De Botton, Stephane
    Tallman, Martin S.
    JOURNAL OF CLINICAL ONCOLOGY, 2017, 35
  • [50] Vorasidenib (VOR; AG-881), an inhibitor of mutant IDH1 and IDH2, in patients (pts) with recurrent/progressive glioma: Updated results from the phase I non-enhancing glioma population.
    Mellinghoff, Ingo K.
    Peters, Katherine B.
    Cloughesy, Timothy Francis
    Burris, Howard A., III
    Maher, Elizabeth Anne
    Janku, Filip
    Cote, Gregory Michael
    De La Fuente, Macarena Ines
    Clarke, Jennifer Leigh
    Kha Le
    Li Liu
    Man Yuen
    Arnofsky, Marissa
    Hassan, Islam
    Steelman, Lori
    Pandya, Shuchi Sumant
    Wen, Patrick Y.
    JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (15)
12345